What changed today in Regulatory: 1 trial update

The signal

NPHLA tracked 1 new official record on this desk today: 1 trial update.

Why this matters

Federal Register documents and FDA notices can change compliance obligations, deadlines and enforcement priorities for pharmacies, compounders and prescribers.

What changed

New trial registered: H24LEAP2 (Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity)[1]
Also reported by STAT: “STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more”.[2]

Who this affects

Pharmacies
503A compounders
503B outsourcing facilities
Pharmacists
Prescribers
Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

[1]
New trial registered: H24LEAP2 (Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity) (opens the source in a new tab)
Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 26, 2026
[2]
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more (opens the source in a new tab)
News reportingSTATOct 27, 2026Industry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.